tbuckley/cabot-search huggingface dataset:
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
Authors: Maria Kleppe, Richard Koche, Lihua Zou, Peter van Galen, Corinne E. Hill, Lauren Dong, Sofie De Groote, Efthymia Papalexi, Amritha V. Hanasoge Somasundara, Keith Cordner, Matthew Keller, Noushin Farnoud, Juan Medina, Erin McGovern, Jaime Reyes, Justin Roberts, Matthew Witkin, Franck Rapaport, Julie Teruya-Feldstein, Jun Qi, Raajit Rampal, Bradley E. Bernstein, James E. Bradner, Ross L. Levine
Journal: Cancer Cell (2018)

(Cancer Cell 33, 29–43; January 8, 2018) In the originally published version of this paper, the spleen histology images for the ruxolitinib- and JQ1-treated mice were the same image. This happened because, during the first revision of our paper, we inadvertently put the same image in both panels. We have gone back and reviewed pathology from nine mice treated with JQ1 in three different trials, and the images are consistent with what we described. We provide here a revised Figure 5, which includes one of those images in a revised Figure 5E. Please note that we show data from a separate cohort of mice treated with vehicle, JQ1, or ruxolitinib (in Figure S4), which is correct and is consistent with the description of the results. This independent experiment shows similar results from JQ1 monotherapy treatment on spleen histopathology. We also identified one additional error in the text description of Figure 2A. The original text stated: To elucidate MPLW515L-dependent gene expression changes, we applied DESeq2 to identify differentially expressed genes (DEGs) (adjusted p value < 0.01 and absolute value of log2-fold change > 1), of which 850 genes were upregulated and 499 genes were downregulated in MPLW515L-expressing MEPs compared with empty vector control cells. The corrected version should be as follows: To elucidate MPLW515L-dependent gene expression changes, we applied DESeq2 to identify differentially expressed genes (DEGs) (adjusted p value < 0.01 and absolute value of log2-fold change > 1), of which 499 genes were upregulated and 850 genes were downregulated in MPLW515L-expressing MEPs compared with empty vector control cells. The images shown in Figure 2A and Table S2 are correct. Both Figure 5 and the legend of Figure 2A have now been corrected in the online version of the paper. The authors apologize for any confusion this may have caused.Figure 5RNA Sequencing Analysis Reveals Inhibitory Effect of JQ1 on TNF/NF-κB Signaling Network (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative NeoplasmsKleppe et al.Cancer CellDecember 14, 2017In BriefKleppe et al. show that aberrant JAK2 signaling in myeloproliferative neoplasms (MPN) leads to chromatin changes that promote NF-κB signaling. BET inhibitors reduce NF-κB-induced inflammation and bone marrow fibrosis in MPN models, and combination treatment with BET and JAK inhibitors shows improved efficacy. Full-Text PDF Open Archive
TREATMENT OF HYPERPOTASSEMIA
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanical Ventilation
Authors: Barry A. Shapiro
Journal: JAMA (1985)

A comprehensive text devoted to performance analysis of positivepressure ventilators is a formidable task, and so the editors should be congratulated for this largely successful attempt. The distinctive value of this work is contained in three chapters accounting for nearly half the text. "Mechanical Ventilation" is composed of 150 pages that concisely, accurately, and comprehensively discuss mechanical ventilators presently available and have excellent illustrations and schematic drawings. This chapter could have been appropriately named "Everything You Wanted to Know About Mechanical Ventilators but Were Afraid to Ask." Two other chapters, "Physical Principles and Functional Design of Ventilators" and "Ventilator Performance Evaluation," are accurate yet simplified enough to be of value to those who have less than a degree in biomedical engineering. These three chapters make this text an essential reference for all personnel involved with the application, evaluation, or maintenance of mechanical ventilators. A most entertaining and enlightening chapter on
Reply
Authors: Angela Ying-Jian Li, David Kong Ann
Journal: Cancer Research (2010)

In Response: Bullerdiek and Rommel raised an interesting question; however, their criticism did not take into account the other measures of repair shown by Li and colleagues (1). Namely, cells expressing endogenous HMGA2 exhibited altered regulation of DNA-PK and led to slower γ-H2AX clearance, which are common measures of DNA repair.Although stem cells are generally characterized by a high degree of genomic stability, the risk of mutation or chromosome aberration increases with each additional cell division (2). Damelin and colleagues (3) have reported that the G2 decatenation checkpoint is highly inefficient in stem and precursor cells, suggesting problems with chromosome segregation due to a deficiency in the decatenation checkpoint during stem cell mitosis. Conceivably, it is possible that the expression of HMGA2 in stem cells affects chromosome stability. Although using 25 metaphases might seem a little low, our observation of an increase in the number of 4n cells in WI-38/HMGA2 is consistent with the results reported by Kuhne and colleagues (4) that the lack of nonhomologous end-joining (NHEJ) component causes the enrichment of cells with 4n DNA content, supporting the notion that an elevated number of cells with 4n or tetraploidy may be caused by the lack of NHEJ repair. Moreover, overexpression of the HMGA family of proteins, HMGA1 or HMGA2, reportedly conveys a deleterious effect on the repair of many different types of DNA lesions, although the detailed mechanisms by which the proteins act to cause this inhibition may vary somewhat (5).Regarding whether the level of HMGA2 expression in transduced WI-38 cell is physiologically relevant, the seemingly massive overexpression of HMGA2 is due to usage of a highly reactive anti-HA antibody in Western blotting. When anti-HMGA2 antibody (BioCheck) was used to probe HMGA2 in the overexpression system, the relative levels of HMGA2 expression were comparable with endogenous levels in various cancer cell lines (Fig. 1). Also, Bullerdiek and Rommel might have been confused that we have used transfection instead of transduction in generating our WI-38/HMGA2 cells. Typically, the number of introduced DNA copy per cell derived from transduction is far less than that from transfection. Taken together, we argue that although Bullerdiek's and Rommel's comment is relevant, we firmly believe that our results support our conclusion that HMGA2 interferes with NHEJ, leading to genome instability.No potential conflicts of interest were disclosed.
JAMA Neurology
Journal: JAMA Neurology (2018)

The mission of JAMA Neurology is to publish scientifi c information primarily important for those physicians caring for people with neurologic disorders but also for those interested in the structure and function of the normal and diseased nervous system.These specifi c aims are (1) to make timely publication of original research of the nervous system, (2) to record observations of single patients or groups of patients that will provide new information and insights,(3) to report more basic research that is pertinent to the understanding of disease, (4) to introduce topics of practice, ethics, teaching, and history that are useful, and (5) to provide a forum for discussion on topics that may be controversial in this fi eld.This information will be published only after extensive peer review so that originality, clarity, and precision are ensured.
Acholest Test Paper Method for Simple Pseudocholinesterase Estimates
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LAW &amp;amp; MEDICINE
Authors: Angela Roddy Holder
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Staff of Bronx Hospital
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Skull radiology in patients with psychiatric illness.
Journal: BMJ (1983)

patients had a personal and four a family history of atopy.Four were smokers; except in these four tobacco smoke was the commonest physical agent provoking rhinorrhoea.Nineteen patients had previously received treatment with oral antihistamines, 18 with topical steroids, and nine with disodium cromoglycate, with no relief of symptoms.Seven patients gave one or more positive results on skin prick testing.Placebo and active drug were delivered by indistinguishable coded pressurised aerosols fitted with nasal adaptors.The dosage of ipratropium was 40 slg to each side of the nose four times a day.All other medication was
Captopril now for mild hypertension?
Authors: J. Henahan
Journal: JAMA (1983)

The manufacturer of captopril (Capoten) is asking the Food and Drug Administration for permission to extend its use to all hypertensive patients. Previously, because of neutropenia, rash, and other potential side effects, captopril was limited to severely ill patients or those who failed to respond to other antihypertensive drugs. Now, however, the manufacturer, E. R. Squibb &amp; Sons, Inc, Princeton, NJ, says recent clinical trials indicate long-term efficacy and a low level of adverse effects in mildly hypertensive patients. The data were discussed at a satellite symposium of the First European Meeting on Hypertension in Milan. Edward Fries, MD, senior medical investigator at the Veterans Administration Medical Center, Washington, DC, and co-chair of the VA's Cooperative Study Group on Antihypertensive Agents, discussed an earlier study involving 475 mildly hypertensive persons (92 to 109 mm Hg diastolic). Blood pressure returned to normal in from half to three fourths of the patients
Cellular Engineering
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)
Authors: Maro Ohanian, Hagop M. Kantarjian, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Elias Jabbour, Marina Konopleva, Susan O'Brien, Alfonso Quintas-Cardama, Bradley G. Somer, Ana Tari, Srdan Verstovsek, William G. Wierda, Jorge E. Cortes
Journal: Blood (2013)
Caprolactam: Condensation of the Carcinogenesis Bioassay Technical Report
Authors: James Huff
Journal: Environmental Health Perspectives (1982)

Caprolactam (aminocaproic lactam, 2-oxohexamethylenimine, CAS No. 105-60-2), the monomer used in the production of nylon-6, was selected and testing initiated by the Carcinogenesis Testing Program, National Cancer Institute (now part of the National Institute of Environmental Health Sciences/National Toxicology Program) because nearly one billion pounds per year are produced, because of the widespread use in food packaging materials and clothing, and because no carcinogenicity stud- ies had been done (1).Nylon 6 resins/fibers are used extensively in carpets, knit fabrics, hosiery, thread, hairbrushes, replacement parts for automobiles and machinery, flotation devices, and food packaging.Highly solu- ble in water, caprolactam reportedly leaches from clothing made from polyamide fibers when soaked in simulated perspiration (2).Ferguson and Wheeler (3) reported irritation of the skin, eyes, nose, and throat in workers occupationally exposed to capro- lactam dust or vapor at concentrations ranging from 10 to 100 ppm. MethodsMale and female inbred Fischer 344 rats and male and female hybrid B6C3F1 mice, obtained from the Frederick Cancer Research Center, were used in this study.Control and treated groups contained 50 animals of each sex and species.For 103 consecu- tive weeks all groups received Ralston Purina Laboratory Chow.Treated groups were fed this
ANTE-NATAL CARE
Journal: BMJ (1939)

any case the two desiderata for successful chemotherapy are (I) absorption of enough of the drug to make the tissue fluids bacter-icidal, and (2) a sufliciently prolonged concentration of the drug in the tissues.The authors ar-e whole-hearted supporters of chemo- therapy plus adjuvant treatment in the formn of protargol 1 in 2,000 or potassium permanganate 1 in 5,000, and hold that by this means a lower dosage of drug is required, less reactions are caused, and the course of the disease is shortened.They also consider that most people use muich too heavy a dosage, and cla(m that in the case of 1399 F. 2 grammes the first day, 1 gramme the second day, and thereafter half a gramme per day are sufficient ; a total dosage of 7 to 8 grammes is effective in favourable cases, while this may be extended to 12 to 14 grammes in cases which do not react so well.For sulphapyridine they recommend 3 grammes the first day, 2 the second, and 1 gramme the third, plus irrigations, and claim that a total of 6 to 7 grammes is sufficient for cure in the great
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients
Authors: E Manesis
Journal: Hepatology (1997)

To compare two interferon (IFN) schedules for the treatment of chronic hepatitis C, we followed 211 patients who received 3 million units IFN-α2b thrice weekly for either 6 months (group 1; 85 patients) or 12 months (group 2; 126 patients), with a median follow-up of 3.4 (0.1- 8.4) and 4.2 (0.7-8.7) years, respectively. The biochemical and virological responses at the end of treatment were 34.1% and 16.5% versus 62.7% and 41.2% for the 6- and the 12-month regimens, respectively. Late biochemical responses (after the third month of treatment) occurred in 30.6% of responding patients, and they were not particularly associated with an adverse long-term treatment outcome. In a multivariate analysis, patients with a primary response were significantly more frequently infected with a non-1b HCV genotype (relative risk [RR]: 14.4), had been treated for 12 months (RR: 6.0), and had an early stage of liver fibrosis (RR: 5.2). Baseline serum HCV-RNA and ferritin levels also bore a significant, though weaker, association with a primary response. Using a set of pretreatment variables in a model of discriminant analysis, we could correctly predict the long-term virological outcome in 86.6% of the individual cases. At the end of follow-up, a biochemical and virological sustained response was observed in 14.1% and 11.8% versus 40.5% and 31% of groups 1 and 2, respectively. Significant predictors of a virological sustained response were a virological primary response (RR: 41.2) and the pretreatment level of serum HCV-RNA (RR: 10.3 per each 106-Eq/mL decrease). Patients with a “good treatment profile,” including an early stage of liver fibrosis, a non-1b genotype and serum HCV-RNA <0.35 × 106 Eq/mL, had a 66.7% rate of observed virological SR, compared with a zero response for those with the opposite, a “bad treatment profile.” We conclude that a 12-month IFN treatment, along with a non-1b genotype and the absence of advanced stage of fibrosis, are the main determinants for the induction of a virological primary response in chronic hepatitis C. Such response, along with a low pretreatment serum HCV-RNA level, are the main predictors for a 4-year virological response to IFN.
Books Received
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: “Prenatal Exposure to Nonpersistent Endocrine Disruptors and Behavior in Boys at 3 and 5 Years”
Authors: Claire Philippat, Dorothy Nakiwala, Antonia M. Calafat, Jérémie Botton, Maria De Agostini, Barbara Heude, Rémy Slama
Journal: Environmental Health Perspectives (2018)